GVAX, a cancer vaccine composed of autologous tumor cells genetically modified to secrete granulocyte-macrophage colony-stimulating factor, was developed40 and showed promise in augmenting tumor-specific immune responses in multiple cancer types.41–43 These advances underline the importance of tumor vaccines in clinical applications for cancer treatment. This evidence concerns the gene CSF2 and cancer.